Search clinical trials for: CYT387

Total 40 results

Creabilis SA

Completed

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

Psoriasis Vulgaris

United States, United Kingdom
Gilead Sciences

Terminated

Efficacy Study of CYT997 in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

Australia
National Institute of Allergy and Infectious Diseases...

Terminated

Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

Idiopathic CD4+ T-Lymphocytopenia

United States
Cytheris SA

Terminated

Study on Interleukin-7 (CYT107) in HIV Patients (Inspire 2)

HIV

United States, Canada
Creabilis SA
LCG Bioscience

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers

Safety
Revimmune
C.R.O. ReSolution Latin America S.A.

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) (ILIAD-7-BRA)

COVID-19 | Lymphocytopenia

Brazil
Revimmune
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Cancer Research... and other collaborators

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) (ILIAD-7-US-O)

COVID-19 | Lymphocytopenia

United States
Revimmune
University Hospital, Limoges; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort (ILIAD-7-FR)

COVID-19 | Lymphocytopenia

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Revimmune

Withdrawn

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Umbilical Cord Blood Transplant
Cytheris, Inc.

Completed

Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

AML | MDS | CML

United States
Revimmune
Washington University School of Medicine

Terminated

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)

Mycobacterium Infections, Nontuberculous

United States
Revimmune
Washington University School of Medicine; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) (ILIAD-7-US-I)

COVID-19 | Lymphocytopenia

United States
Revimmune
Amarex Clinical Research

Terminated

InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort (ILIAD-7-UK)

COVID-19 | Lymphocytopenia

United Kingdom
Creabilis SA
Aalborg University Hospital

Completed

A Study to Investigate the Pharmacodynamic Effects of CT327 on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers

Neuropathic Pain

Denmark
Cytheris SA

Completed

Safety Study of IL-7 in HIV-infected Patients (Inspire)

HIV Infections | Lymphopenia

United States, France, Canada, Italy
Creabilis SA

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis

Atopic Dermatitis

United Kingdom
Gilead Sciences

Terminated

Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma

Glioblastoma Multiforme

Australia
Sierra Oncology, Inc.

Completed

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada
Sierra Oncology, Inc.

Completed

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
Sierra Oncology, Inc.

Completed

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
GlaxoSmithKline

Active, not recruiting

Extended Access of Momelotinib in Adults With Myelofibrosis

Neoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands
Creabilis SA

Withdrawn

CT 327 in the "Atopy Patch Test" Model (CT327 AD01-09)

Atopic Dermatitis

Germany
Sierra Oncology LLC - a GSK company

Completed

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Primary Myelofibrosis (PMF) | Post-polycythemia Vera (Post-PV) Myelofibrosis | Postessential Thrombocythemia (Post-ET) Myelofibrosis

United States, Canada
Sierra Oncology, Inc.

Terminated

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Polycythemia Vera | Essential Thrombocythemia

United States, France, Germany, Canada, Australia
Sierra Oncology LLC - a GSK company

Completed

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Canada, Germany, Australia
Revimmune
Washington University School of Medicine; Vanderbilt University School of Medicine

Completed

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-B)

Severe Sepsis With Septic Shock

United States
Cytheris SA

Terminated

Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders (Inspire 3)

HIV

Switzerland, Italy, South Africa
Revimmune
Washington University School of Medicine; University Hospital, Limoges; George...

Terminated

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-C&D)

Sepsis, Severe

United States, France
Sierra Oncology, Inc.

Terminated

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Cancer Immunotherapy Trials Network

Completed

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone

United States
LUCINDA BATEMAN, MD

Completed

Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (InTiME)

Chronic Fatigue Syndrome | Myalgic Encephalomyelitis

United States
Sierra Oncology, Inc.

Terminated

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

United States
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
Sierra Oncology, Inc.

Terminated

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

United States
Cytheris SA

Unknown

Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients (CONVERT)

Chronic Hepatitis B

France, Italy
Sierra Oncology, Inc.

Completed

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Simplify 2)

Primary Myelofibrosis (PMF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Post-polycythemia Vera (Post-PV)

United States, Canada, France, Italy, Germany, Spain, Israel, United Kingdom
Sierra Oncology LLC - a GSK company

Terminated

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Sierra Oncology LLC - a GSK company

Completed

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Canada, Hungary, Israel, Spain, United States, Australia, Taiwan, Singapore, Germany, Italy, France, Belgium, New Zealand, Austria, United Kingdom, Denmark, Bulgaria, Poland, Czechia, Romania, Sweden
Newron Pharmaceuticals SPA

Completed

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist (MOTION)

Idiopathic Parkinson's Disease

United States, Spain, Brazil, Peru, Colombia, Germany, Argentina, India, Croatia, Czech Republic, Italy, South Africa, Finland, Portugal, Canada, Slovakia, Bulgaria, Chile, Mexico, Poland
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder... and other conditions

United States

Search clinical trials for: CYT387

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations